J Med Cases
Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website http://www.journalmc.org

Case Report

Volume 9, Number 1, January 2018, pages 23-25


The Challenge of Tuberculosis Infection Related to Adalimumab: A Subtle and Rare Presentation

Juliana Lopesa, e, Ana Machadoa, Sara Martinsa, Sara Piresa, Catarina Brancoa, Joana Fragosob, Diogo Guerrab, Patricia Camposc, Mariana Brandaoa, d, Graziela Carvalheirasc, d, Teresa Mendoncaa, d

aInternal Medicine Department, Centro Hospitalar do Porto, Porto, Portugal
bInfectious Diseases Department, Centro Hospitalar do Porto, Porto, Portugal
cIntensive Care Department, Centro Hospitalar do Porto, Porto, Portugal
dClinic Immunology Unit, Centro Hospitalar do Porto, Porto, Portugal
eCorresponding Author: Juliana Lopes, Internal Medicine Department, Centro Hospitalar do Porto, Hospital de Santo Antonio, Largo Prof. Abel Salazar, 4099-001, Porto, Portugal

Manuscript submitted December 3, 2017, accepted December 8, 2017
Short title: Muscle Tuberculosis and Adalimumab
doi: https://doi.org/10.14740/jmc2979w

Abstract▴Top 

With the increasing use of biological therapies, there was a concomitant increase in concern and sensitivity for associated opportunistic infections. There has been growing evidence that anti-tumor necrosis factor (TNF) therapy increases the risk of opportunistic infection. Screening for latent tuberculosis (TB) prior to initiation of therapy has reduced the incidence of active TB, although it is not completely preventable. The possibility of active TB should always be considered in immunosuppressed patients under anti-TNF therapy. We report a case of muscular TB with psoas abscess in a patient under adalimumab. This case highlights the importance of the high suspicion threshold for Mycobacterium tuberculosis infection, in patients with subtle symptoms.

Keywords: Tuberculosis; Psoas muscle abscess; Anti-TNF; Adalimumab; Intestinal Behcet

Introduction▴Top 

The use of anti-tumor necrosis factor (TNF) has dramatically improved the approach to immune-mediated diseases. However, there is a concomitant increase in concern and sensitivity for associated opportunistic infections [1]. These agents suppress activity of TNF, a proinflammatory cytokine crucial for human response to infection. In fact, several opportunistic infections have been described in association with therapy with anti-TNF [2, 3]. The first randomized anti-TNF trial has described only one case of tuberculosis (TB) infection. Since then, there has been growing evidence that anti-TNF therapy increases the risk of TB infection, with a possible difference between the three anti-TNF drugs used: infliximab and adalimumab with higher associated risk than etanercept [4, 5].

Screening for latent TB prior to initiation of therapy has reduced the incidence of active TB, although it is not completely preventable. There are cases of disease reactivation even after adequate treatment at the start of biological therapy. The possibility of active TB should always be considered in cases with suggestive clinical features or suspect imaging findings, even after chemoprophylaxis [3, 6]. Portugal has an intermediate incidence of TB (22 cases per 100,000 inhabitants in 2016) compared to the rest of Europe; as a result, patients on anti-TNF therapy will have, therefore, a higher incidence of infection [7, 8]. Different from the presentation of the infection in immunocompetent patients, an infection by Mycobacterium tuberculosis associated with TNF blockade is more commonly as an extrapulmonary presentation. As described by Keane et al, of the 70 documented cases of TB infection with anti-TNF treatment, 57% were extrapulmonary and 25% disseminated [4].

We report a rare case of extrapulmonary TB in a patient using adalimumab.

Case Report▴Top 

This was a 59-year-old woman, Caucasian, with a previous history of osteoarticular TB (Pott’s disease) at the age of 7 years old. Since then, she had no history of infection or contact with other TB patients.

She was diagnosed as Behcet’s disease with a 23-year-old history of outbreaks of oral ulcers. Since the age of 55 years, she started with severe gastrointestinal manifestations, irresponsive to corticosteroids and infliximab. She began adalimumab treatment 3 years ago with clinical improvement. Before anti-TNF therapy, she completed 9 months of isoniazid for latent tuberculosis.

The patient presented with high fever, asthenia and night sweats for 1 month, without other symptoms associated. Blood tests were innocent, with a slight protein C elevation. Blood and urine cultures were sterile. Pulmonary X-ray and abdominal ultrasound didn’t reveal any findings. After 2 weeks of the first symptoms, she complained with left pain, without trauma associated. Computed tomography (CT) scan revealed a left psoas muscle mass (diameter 4 - 14 cm with calcifications) (Fig. 1). She was submitted to percutaneous drainage of the abscess and the microbiologic study revealed nucleic acid amplification (NAA) test positive for Mycobacterium tuberculosis, which was also detected in cultures.

Figure 1.
Click for large image
Figure 1. Abdominal CT scan showing left psoas muscle mass with the diameter 4 - 14 cm. CT: computed tomography.

The patient began treatment with classic association of antibiotics that included isoniazid, rifampicin, pyrazinamide, and ethambutol for 9 months with complete resolution of the abscess (Fig. 2).

Figure 2.
Click for large image
Figure 2. Abdominal CT scan with resolution of the abscess after 9 months of antibacillar therapy.
Discussion▴Top 

The introduction of anti-TNF therapy drastically altered the approach to immune-mediated diseases. TNF plays a key role in host defence against Mycobacterium tuberculosis, mediating granuloma formation and homeostasis and consequent bacilli content in latent TB infection [9]. Consequently, a number of cases of TB have been documented in patients under anti-TNF therapy such as etanercept, infliximab, and adalimumab [10]. This risk appears to be 3 to 4 times higher with infliximab and adalimumab when compared to etanercept [11]. It is believed that most cases are consecutive of latent TB reactivation and therefore, in countries with high or intermedium incidence, the screening is recommended before initiation of therapy and treated accordingly. Several studies have shown that chemoprophylaxis of latent TB before or during anti-TNF therapy reduces the risk of reactivation and consequently more severe forms of infection [9].

In clinical trials prior to the screening for TB, only 7 cases of active infection were reported in Europe. After the introduction of the screening in adalimumab clinical trials, there was an increase in the number of cases to 23 cases until 2005 and 59 cases until 2014 [12, 13].

In the present case, the active infection was documented despite screening and treatment of latent TB, and is a rare extrapulmonary presentation.

The psoas abscess was first described in 1881[14] and remains a rare infection in developed countries. It can be termed as primary if the focus is unknown or by hematogenous spread or secondary if there is an abdominal or retroperitoneal infection. It is usually caused by Staphylococcus aureus, or other agents present in intestinal flora [15]. The immunosuppression is one of the major associated risk factors and for this reason, agents such as Mycobacterium tuberculosis should be considered.

Although several cases of extrapulmonary infection have been described [16-19], the authors only found one case of muscular TB in patients with adalimumab in literature [20].

This case highlights the importance of the high suspicion threshold for Mycobacterium tuberculosis infection. In immunocompromised patients, the clinical presentation is usually very subtle, extrapulmonary and rare forms are more frequent and may progress rapidly to more severe forms. Adequate early and therapeutic diagnosis will allow improving the long-term prognosis with resolution of the infection.

Conflict of Interest

There is no conflict of interest.

Financial Support

No external funds were used for this research study.


References▴Top 
  1. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, Bassetto F, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87(3):385-395.
    doi pubmed
  2. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore). 2005;84(5):291-302.
    doi
  3. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265.
    doi pubmed
  4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-1104.
    doi pubmed
  5. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39(3):295-299.
    doi pubmed
  6. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10(10):1127-1132.
    pubmed
  7. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domenech E, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3(2):47-91.
    doi pubmed
  8. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NCSA 3.0 IGO.
  9. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148-155.
    doi
  10. Keystone EC. Safety of biologic therapies - an update. J Rheumatol Suppl. 2005;74:8-12.
    doi
  11. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Consortium BSRBRCC, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522-528.
    doi pubmed
  12. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889-894.
    doi pubmed
  13. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47-55.
    doi pubmed
  14. Mynter H. Acute psoitis. Buffalo Med Surg J. 1881;21:202-210.
  15. Ricci MA, Rose FB, Meyer KK. Pyogenic psoas abscess: worldwide variations in etiology. World J Surg. 1986;10(5):834-843.
    doi pubmed
  16. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, Miguel-de la Villa F. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol. 2007;26(3):452-453.
    doi pubmed
  17. Efde MN, Houtman PM, Spoorenberg JP, Jansen TL. Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment. Neth J Med. 2005;63(3):112-114.
    pubmed
  18. Lertxundi U, Mayo J, Garcia M, Ruiz B, Aguirre C. Tuberculoses miliar tras tratamiento con adalimumab. Farm Hosp. 2005;29(5):343-347.
    doi
  19. Abreu C, Magro F, Santos-Antunes J, Pilao A, Rodrigues-Pinto E, Bernardes J, Bernardo A, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis. 2013;7(10):e486-492.
    doi pubmed
  20. Azevedo VF, Parchen C, Coelho SA, Lacerda DC, Hirth CG. Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab. Rheumatol Int. 2009;29(11):1381-1384.
    doi pubmed


This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Medical Cases is published by Elmer Press Inc.

 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!